Siddharth Singh¹ and Pooja Singh Gaur², Surya Kant² and Rachna Chaturvedi¹*

¹Amity Institute of Biotechnology, Amity University, Uttar Pradesh, Lucknow Campus, Gomti Nagar Extension, Lucknow, India
¹Department of Pulmonary Medicine, KGMU, Lucknow, India

*Corresponding Author: Rachna Chaturvedi, Amity Institute of Biotechnology, Amity University, Uttar Pradesh, Lucknow Campus, Gomti Nagar Extension, Lucknow, India.

Received: March 18, 2025; Published: April 10, 2025

Abstract

Over the last few decades, the increase in Acinetobacter infections among critically ill patients has been a growing concern and it has become important as a major nosocomial pathogen, partially due to its impressive genetic capabilities to acquire resistance and partially due to its high selective pressure, especially in intensive care units. Bacteraemia, pneumonia, urinary tract, and skin and soft tissue infections are the utmost frequent presentations of Acinetobacter baumannii with attributable death rates considering 35%. A. baumannii is progressively connected with several epidemics, demonstrating determined trouble due to the extensive level of antimicrobial resistance and clinical manifestations. Initially a low-virulence bacterium, it has evolved into a multidrug-resistant pathogen that is now a threat to medical professionals and hospitalized patients everywhere. To control hospital outbreaks of multidrug resistance Acinetobacter infection, we need to contain their dispersion or bear new medicines or rational combination therapy. The best course of action for treating multidrug-resistant Acinetobacter infections is still unclear, and practical therapy still depends on understanding the susceptibility patterns of isolates from the patient's institution. Thus, the troublesome distribution of biofilmproducing species in multidrug-resistant inhabitants of A. baumannii poses a meaningful treatment task. This review is mainly concentrated on general features and introduction to Acinetobacter and its epidemiological status, antibiotic resistance, and strategies to control infection to minimize spread.

Keywords: Acinetobacter baumannii; Biofilm Formation; Multi-resistance; Nosocomial Infections; Compromised Immune System

References

1. Howard A., et al. “Acinetobacter baumannii: an emerging opportunistic pathogen”. Virulence 3 (2012): 243-250.
2. Falagas ME., et al. “Acinetobacter infections: a growing threat for critically ill patients”. Epidemiology and Infection8 (2008): 1009-1019.
3. Rice LB. “Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE”. Journal of Infectious Disease8 (2008): 1079-1081.
4. Nemec A., et al. “Genotypic and phenotypic characterization of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex with the proposal of Acinetobacter pitty sp. nov. (formerly Acinetobacter genomic species 3) and Acinetobacter nosocomialis sp. nov. (formerly Acinetobacter genomic species 13TU)”. Research Microbiology4 (2011): 393-404.
5. Kempf M and Rolain JM. “The emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options”. International Journal of Antimicrobial Agents2 (2012): 105-114.
6. Richards AM., et al. “Code blue: Acinetobacter baumannii, a nosocomial pathogen with a role in the oral cavity”. Molecular Oral Microbiology1 (2015): 2-15.
7. Dijkshoorn L., et al. “An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii”. Nature Reviews Microbiology12 (2007): 939-951.
8. Munoz-Price L S and Weinstein R A. “Acinetobacter infection”. New England Journal of Medicine12 (2008): 1271-1281.
9. Peleg A Y., et al. “Acinetobacter baumannii: emergence of a successful pathogen”. Clinical Microbiology Reviews3 (2008): 538-582.
10. Giamarellou H. “Multidrug-resistant Gram-negative bacteria: how to treat and for how long”. International Journal of Antimicrobial Agents 36 (2010): S50-S54.
11. McConnell MJ., et al. “Acinetobacter baumannii-associated skin and soft tissue infections: recognizing a broadening spectrum of disease”. Surgery Infectious (Larchmt). 13.6 (2012): 347-352.
12. Pérez F., et al. “Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options”. Seminars in Respiratory and Critical Care Medicine 1 (2015): 085-098.
13. Munoz-Price LS., et al. “Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases”. Lancet Infectious Disease9 (2013): 785-796.
14. Peleg AY., et al. “Acinetobacter baumannii: emergence of a successful pathogen”. Clinical Microbiology Review3 (2008): 538-582.
15. Doi Y., et al. “Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options”. Seminars in Respiratory and Critical Care Medicine 1 (2015): 085-098.
16. Dijkshoorn L., et al. “Acinetobacter baumannii: a global threat”. Infection Control and Hospital Epidemiology 12 (2007): 1239-1242.
17. Adams-Haduch JM., et al. “The outbreak of colistin-resistant, carbapenemase-producing Klebsiella pneumoniae in metropolitan Detroit, Michigan”. Antimicrobial Agents and Chemotherapy12 (2014): 6993-6997.
18. Antunes LCS., et al. “Acinetobacter spp. as nosocomial pathogens: epidemiology and resistance features”. Revista da Sociedade Brasileira de Medicina Tropical 3 (2014): 287-293.
19. Murray CK., et al. “Acinetobacter infection in the ICU: how to fight an increasing threat to patient safety”. Surgery Infectious (Larchmt)3 (2010): 283-289.
20. Scott P., et al. “Combat-related extremity injuries and infection”. The Journal of Trauma and Acute Care Surgery 1 (2016): S108-S110.
21. Wong D., et al. “Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges”. Clinical Microbiology Review1 (2017): 409-447.
22. Sarshar M., et al. “Acinetobacter baumannii: An Ancient Commensal with Weapons of a Pathogen”. Pathogens4 (2021): 387.
23. Erica N., et al. “Infectious Complications of Open Type III Tibial Fractures among Combat Casualties”. Clinical Infectious Diseases4 (2007): 409-415.
24. Ki Tae Kwon., et al. “Impact of imipenem resistance on mortality in patients with Acinetobacter bacteremia”. Journal of Antimicrobial Chemotherapy3 (2007): 525-530.
25. Medina J., et al. “Prospective study of risk factors for ventilator-associated pneumonia caused by Acinetobacter species”. Journal of Critical Care1 (2007): 18-26.
26. Perez F., et al. “The global challenge of multidrug-resistant Acinetobacter baumannii”. Antimicrobial Agents and Chemotherapy10 (2007): 3471-3484.
27. Preeti Chandra., et al. “Isolation, Characterization and Antibacterial Susceptibility test of Acinetobacter Species Obtained from Tertiary Care Hospital”. International Journal of Current Microbiology and Applied Sciences 2 (2017): 1279-1286.
28. Vila J., et al. “In vitro antimicrobial production of beta-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii”. Antimicrobial Agents and Chemotherapy 1 (1993): 138-141.
29. Tankovic J., et al. “Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic typing methods”. Journal of Clinical Microbiology11 (1994): 2677-2681.
30. Misung K., et al. “Genomic and phenotypic analyses of multidrug-resistant Acinetobacter baumannii NCCP 16007 isolated from a patient with a urinary tract infection”. Virulence1 (2020): 150-164.
31. Sugawara E and Nikaido H. “OmpA is the principal nonspecific slow porin of Acinetobacter baumannii”. Journal of Bacteriology15 (2012): 4089-4096.
32. Iyer R., et al. “Acinetobacter baumannii OmpA Is a Selective Antibiotic Permeant Porin”. ACS Infectious Disease3 (2018): 373-381.
33. Zhong X., et al. “In Vivo, Cross-Linking MS Reveals Conservation in OmpA Linkage to Different Classes of β-Lactamase Enzymes”. Journal of the American Society for Mass Spectrometry 2 (2020): 190-195.
34. Cecchini T., et al. “Deciphering Multifactorial Resistance Phenotypes in Acinetobacter baumannii by Genomics and Targeted Label-free Proteomics”. Molecular Cell Proteomics3 (2018): 442-456.
35. Huang L., et al. “Differential susceptibility to carbapenems due to the AdeABC efflux pump among nosocomial outbreak isolates of Acinetobacter baumannii in a Chinese hospital”. Diagnostic Microbiology and Infectious Disease 3 (2018): 326-332.
36. Hawkey J., et al. “Evolution of carbapenem resistance in Acinetobacter baumannii during a prolonged infection”. Microbial Genomics3 (2018): e000165.
37. Vila J., et al. “Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii”. Journal of Antimicrobe and Chemotherapy 59 (2007): 1210-1215.
38. Magnet S., et al. “Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454”. Antimicrobial Agents and Chemotherapy 12 (2001): 3375-3380.
39. Sauvage E., et al. “The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis”. FEMS in Microbiology Review2 (2008): 234-258.
40. Zapun A., et al. “Penicillin-binding proteins and beta-lactam resistance”. FEMS in Microbiology Review2 (2008): 361-385.
41. Cayô R., et al. “Analysis of genes encoding penicillin-binding proteins in clinical isolates of Acinetobacter baumannii”. Antimicrobial Agents and Chemotherapy 12 (2011): 5907-5913.
42. Siegel JD., et al. “Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings”. (2007).
43. Panagiotis G., et al. “Impact of an antibiotic restriction policy on the antibiotic resistance patterns of Gram-negative microorganisms in an Intensive Care Unit in Greece”. International Journal of Antimicrobial Agents (2007).
44. Coelho JM., et al. “Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England”. Journal of Clinical Microbiology10 (2006): 3623-3627.

Citation

Citation: Rachna Chaturvedi., et al. “Acinetobacter: An Emerging Threat to Hospitalized Patients".Acta Scientific Microbiology 8.5 (2025): 25-34.

Copyright

Copyright: © 2025 Rachna Chaturvedi., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.